Holen Sie sich die Stockscreener-App
14.46
3.29%
-0.4471
Schlusskurs vom Vortag:
$14.91
Offen:
$15.22
24-Stunden-Volumen:
452.63K
Relative Volume:
0.25
Marktkapitalisierung:
$1.16B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-149.96M
KGV:
-7.9822
EPS:
-1.8119
Netto-Cashflow:
$-134.67M
1W Leistung:
-33.09%
1M Leistung:
-36.17%
6M Leistung:
+85.59%
1J Leistung:
+229.98%
1-Tages-Spanne:
$14.41
$15.50
1-Wochen-Bereich:
$12.99
$18.62
52-Wochen-Spanne:
$2.86
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Firmenname
Olema Pharmaceuticals Inc
Sektor
Branche
Telefon
(415) 651-3316
Adresse
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
14.42 | 1.20B | 0 | -149.96M | -134.67M | -1.8119 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.80 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.16 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.52 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.65 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.37 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-11 | Eingeleitet | Stifel | Buy |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-12 | Bestätigt | Citigroup | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2024-01-30 | Eingeleitet | Citigroup | Buy |
| 2023-07-21 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-05 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-22 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-12-14 | Eingeleitet | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
Assessing Olema Pharmaceuticals (OLMA) Valuation After Breast Cancer Trial Setback Hits Sector Sentiment - simplywall.st
HC Wainwright Has Negative Forecast for OLMA FY2029 Earnings - MarketBeat
Momentum Shift: Will Olema Pharmaceuticals Inc outperform its industry peersMarket Trend Review & Weekly Top Gainers Trade List - baoquankhu1.vn
What's Going On With Olema Pharmaceuticals Stock On Wednesday? - Benzinga
Does Olema Pharmaceuticals (OLMA) Still Stand Apart After Roche’s Breast Cancer Trial Setback? - Sahm
H.C. Wainwright does not see direct read from Roche miss to Olema’s OPERA-02 - Yahoo Finance
Olema Pharmaceuticals (OLMA) to Release Quarterly Earnings on Tuesday - MarketBeat
Oppenheimer, Cowen, H.C. Wainwright Maintain Buy/Outperform on OLMA March 2026 - Meyka
Olema Pharmaceuticals (OLMA) Maintains Buy Rating Despite Lowered Price Target | OLMA Stock News - GuruFocus
Olema Pharmaceuticals (OLMA) Stock Plummets 41% on Roche Trial Disappointment - MEXC
H.C. Wainwright cuts Olema Pharmaceuticals price target on trial data By Investing.com - Investing.com Canada
Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Benzinga
Stifel reiterates Buy on Olema stock after Roche trial miss By Investing.com - Investing.com Canada
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down Following Analyst Downgrade - MarketBeat
HC Wainwright Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $38.00 - MarketBeat
Olema Pharmaceuticals Faces Strategic Shifts Amid Market Turbulence - StocksToTrade
Oppenheimer reiterates Olema Pharmaceuticals stock rating at Outperform By Investing.com - Investing.com Canada
Olema Pharmaceuticals (OLMA) Stock Crashes After Roche Breast Cancer Trial Fails - CoinCentral
Olema Pharmaceuticals stock tumbles 41% on Roche trial data By Investing.com - Investing.com Canada
Why Is Olema Pharmaceuticals Stock Dropping On Monday? - Bitget
Olema earnings loom as analysts eye palazestrant potential - Investing.com Australia
Olema earnings loom as analysts eye palazestrant potential By Investing.com - Investing.com India
Institution Moves: Is Olema Pharmaceuticals Inc stock trending bullish2025 Short Interest & Weekly Breakout Watchlists - baoquankhu1.vn
Shawnte Mitchell Sells 15,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Insider Shawnte Mitchell Sells 25,000 Shares - MarketBeat
Aug Intraday: Is Olema Pharmaceuticals Inc backed by strong institutional buyingPortfolio Value Report & Smart Money Movement Alerts - baoquankhu1.vn
Olma Health (NASDAQ: OLMA) director reports several stock sales in Jan–Feb 2026 - Stock Titan
Insider sells 15,000 OLMA shares; 25,000-share option sale planned (OLMA) - Stock Titan
OLMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Olema Pharmaceuticals Grants Stock Options to New Employees Under 2022 Inducement Plan - Quiver Quantitative
[144] Olema Pharmaceuticals, Inc. SEC Filing - Stock Titan
How Leadership Turnover and Palazestrant Optimism At Olema Pharmaceuticals (OLMA) Has Changed Its Investment Story - Sahm
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Olema Pharmaceuticals CEO to join TDCowen Health Care Conference fireside chat in Boston - Traders Union
Olema Pharmaceuticals CEO Touts Palazestrant Edge as Oral SERDs Shake Out at Conference - MarketBeat
How Leadership Turnover During Key Trial Milestones Will Impact Olema Pharmaceuticals (OLMA) Investors - Yahoo Finance
Olema Pharmaceuticals (OLMA) Valuation Check After Recent Share Price Volatility - simplywall.st
OLMA Should I Buy - Intellectia AI
Citi, Stifel Bullish on Olema (OLMA) Despite COO Departure - Yahoo Finance
Olema earnings on deck: Biotech faces widening loss ahead of key data By Investing.com - Investing.com South Africa
Olema earnings on deck: Biotech faces widening loss ahead of key data - Investing.com Australia
Olema Pharmaceuticals, Inc. (OLMA): Investor Outlook on a Promising Biotech with 91% Potential Upside - DirectorsTalk Interviews
20,000-share Form 144 filed for Olami Medical (NASDAQ: OLMA) - Stock Titan
Olema Pharmaceuticals CEO Spotlights Phase 3 Palazestrant Trials, KAT6 Program at Citi Summit - MarketBeat
Shane Kovacs sells 110,000 OLMA shares across Jan–Feb 2026 (NASDAQ: OLMA) - Stock Titan
OLMA (NASDAQ: OLMA) Form 144 shows proposed 20,000-share sale; prior insider sales listed - Stock Titan
Is CytomX Therapeutics Inc stock showing strong momentumJuly 2025 Sector Moves & Low Risk High Reward Ideas - baoquankhu1.vn
OLMA Technical Analysis & ETF Price Forecast - Intellectia AI
Aug Drivers: Can JetBlue Airways Corporation reach resistance levels soonQuarterly Profit Report & Risk Managed Investment Signals - baoquankhu1.vn
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times
Finanzdaten der Olema Pharmaceuticals Inc-Aktie (OLMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):